WO2003068801A3 - Antibody variants with faster antigen association rates - Google Patents
Antibody variants with faster antigen association rates Download PDFInfo
- Publication number
- WO2003068801A3 WO2003068801A3 PCT/US2003/004184 US0304184W WO03068801A3 WO 2003068801 A3 WO2003068801 A3 WO 2003068801A3 US 0304184 W US0304184 W US 0304184W WO 03068801 A3 WO03068801 A3 WO 03068801A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody variants
- association rates
- antigen association
- faster
- faster antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03739759A EP1573002A4 (en) | 2002-02-11 | 2003-02-11 | Antibody variants with faster antigen association rates |
AU2003216250A AU2003216250A1 (en) | 2002-02-11 | 2003-02-11 | Antibody variants with faster antigen association rates |
BR0307548-6A BR0307548A (en) | 2002-02-11 | 2003-02-11 | Method of producing an antibody variant, antibody variant, composition, isolated nucleic acid, vector, host cell, process for producing an antibody variant, and method of determining the antigen association coefficient of an antibody |
JP2003567927A JP2006506943A (en) | 2002-02-11 | 2003-02-11 | Antibody variants with high antigen binding rate |
CA002472922A CA2472922A1 (en) | 2002-02-11 | 2003-02-11 | Antibody variants with faster antigen association rates |
MXPA04007583A MXPA04007583A (en) | 2002-02-11 | 2003-02-11 | Antibody variants with faster antigen association rates. |
KR10-2004-7012316A KR20040082421A (en) | 2002-02-11 | 2003-02-11 | Antibody Variants with Faster Antigen Association Rates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35589502P | 2002-02-11 | 2002-02-11 | |
US60/355,895 | 2002-02-11 | ||
US40968502P | 2002-09-10 | 2002-09-10 | |
US60/409,685 | 2002-09-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003068801A2 WO2003068801A2 (en) | 2003-08-21 |
WO2003068801A3 true WO2003068801A3 (en) | 2005-06-30 |
Family
ID=27737510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/004184 WO2003068801A2 (en) | 2002-02-11 | 2003-02-11 | Antibody variants with faster antigen association rates |
Country Status (9)
Country | Link |
---|---|
US (4) | US20030224397A1 (en) |
EP (1) | EP1573002A4 (en) |
JP (1) | JP2006506943A (en) |
KR (1) | KR20040082421A (en) |
AU (1) | AU2003216250A1 (en) |
BR (1) | BR0307548A (en) |
CA (1) | CA2472922A1 (en) |
MX (1) | MXPA04007583A (en) |
WO (1) | WO2003068801A2 (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003087131A2 (en) | 2002-04-10 | 2003-10-23 | Genentech, Inc | Anti-her2 antibody variants |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) * | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
US8597911B2 (en) * | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
KR20120090094A (en) * | 2003-06-13 | 2012-08-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | Aglycosyl anti-cd154(cd-40 ligand) antibodies and uses thereof |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
CA2561264A1 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US20050227289A1 (en) * | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
US20060018902A1 (en) * | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
CA2575838A1 (en) * | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP2008531060A (en) * | 2005-03-04 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | A method for humanizing immunoglobulin variable regions via rational modification of complementarity determining residues |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US20100261288A1 (en) | 2005-06-13 | 2010-10-14 | Fortebio, Inc. | Tip tray assembly for optical sensors |
AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
EP1951757B1 (en) | 2005-10-06 | 2014-05-14 | Xencor, Inc. | Optimized anti-cd30 antibodies |
ME00380B (en) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US20070161042A1 (en) * | 2006-01-11 | 2007-07-12 | Fortebio, Inc. | Methods for characterizing molecular interactions |
MY169492A (en) * | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
CN105177091A (en) * | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | Antibody modification method for purifying bispecific antibody |
WO2007114319A1 (en) * | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
ES2402591T3 (en) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Optimized antibodies that target CD19 |
WO2008033535A2 (en) * | 2006-09-14 | 2008-03-20 | Fortebio, Inc. | Amine-reactive biosensor |
AU2007299843B2 (en) | 2006-09-18 | 2012-03-08 | Xencor, Inc | Optimized antibodies that target HM1.24 |
WO2008063932A2 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (en) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for treating or preventing breast cancer. |
TWI432449B (en) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | Variants derived from actriib and uses therefor |
TW201808334A (en) | 2007-02-09 | 2018-03-16 | 艾瑟勒朗法瑪公司 | Pharmaceutical composition comprising an ActRIIa-Fc fusion protein; use of an ActRIIa-Fc fusion protein for treatment or prevention of cancer-related bone loss; use of an ActRIIa-Fc fusion protein for the treatment or prevention of multiple myeloma |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
EP3789400A1 (en) * | 2007-09-26 | 2021-03-10 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP3825329A1 (en) | 2007-12-26 | 2021-05-26 | Xencor, Inc. | Fc variants with altered binding to fcrn |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
SI2275443T1 (en) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
BRPI0910482A2 (en) | 2008-04-29 | 2019-09-24 | Abbott Lab | double variable domain immunoglobins and their uses |
ES2549903T3 (en) * | 2008-05-07 | 2015-11-03 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon alfa |
EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG191625A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
DK3750552T3 (en) | 2008-08-14 | 2023-07-24 | Acceleron Pharma Inc | GDF TRAPS |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
JP5787446B2 (en) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | Antibody constant region variants |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2918602A1 (en) | 2009-04-16 | 2015-09-16 | AbbVie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
WO2010129532A2 (en) * | 2009-05-05 | 2010-11-11 | Trustees Of Boston University | Method and device for rapid detection of bacterial antibiotic resistance/susceptibility |
JP5912078B2 (en) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ, インコーポレイテッド | Methods for increasing thermogenic adipocytes |
JP2012529294A (en) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ, インコーポレイテッド | Cleaved ActRIIB-Fc fusion protein |
ES2656446T3 (en) * | 2009-06-17 | 2018-02-27 | Abbvie Biotherapeutics Inc. | Anti-VEGF antibodies and their uses |
KR20120060877A (en) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011037158A1 (en) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | Modified antibody constant regions |
JP2013507928A (en) | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
US8937159B2 (en) | 2009-12-16 | 2015-01-20 | Abbvie Biotherapeutics Inc. | Anti-HER2 antibodies and their uses |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
FR2958753B1 (en) * | 2010-04-13 | 2018-03-16 | Institut De Recherche Pour Le Developpement (Ird) | ANTIGENIC CONSTRUCTION AND ITS APPLICATIONS FOR THE DETECTION OF TRYPANOSOMOSES IN MAN AND ANIMALS |
KR20130036012A (en) * | 2010-05-07 | 2013-04-09 | 에프. 호프만-라 로슈 아게 | Diagnostic method for the detection of cells ex vivo |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
JP5682976B2 (en) * | 2010-09-17 | 2015-03-11 | 国立大学法人東北大学 | Method for determining the effectiveness of pharmaceuticals containing antibodies as components |
JP2014502260A (en) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | ACTRIIA binders and uses thereof |
TWI452135B (en) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
JP5900489B2 (en) * | 2011-03-25 | 2016-04-06 | コニカミノルタ株式会社 | Immunohistochemical staining method and method for determining the effectiveness of an antibody drug using the same |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
MX2014008101A (en) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Dual variable domain immunoglobulins against il-13 and/or il-17. |
US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
RU2636043C2 (en) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Anti-vegf/dll4-immunoglobulins with double variable domains and their application |
RU2678117C2 (en) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Activin-actrii antagonists and uses thereof for treating bone and other disorders |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
BR112015023797A2 (en) | 2013-03-15 | 2017-10-24 | Abbvie Inc | dual specificity binding proteins directed against il-1b and / or il-17 |
DK3050896T3 (en) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Process for the preparation of a polypeptide heteromultimer |
MA40008A (en) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | ANTAGONIST ACTRII FOR THE TREATMENT AND PREVENTION OF SKIN ULCER IN A SUBJECT WITH ANEMIA |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
MA41052A (en) | 2014-10-09 | 2017-08-15 | Celgene Corp | TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS |
EP4233889A3 (en) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
KR101860280B1 (en) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
RU2730590C2 (en) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Composition for treating diseases associated with il-6 |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
WO2017115773A1 (en) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Method for promoting efficiency of purification of fc region-containing polypeptide |
SG10202007025PA (en) | 2016-03-14 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
CA3019426A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
TW202034958A (en) * | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632926B1 (en) * | 1998-11-18 | 2003-10-14 | Genentech, Inc. | Antibody variants |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550362A (en) * | 1895-11-26 | crosby | ||
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP2301580B1 (en) * | 1997-04-07 | 2012-01-18 | Genentech, Inc. | Container holding anti-VEGF antibodies |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
WO2001062931A2 (en) * | 2000-02-25 | 2001-08-30 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
-
2003
- 2003-02-11 CA CA002472922A patent/CA2472922A1/en not_active Abandoned
- 2003-02-11 EP EP03739759A patent/EP1573002A4/en not_active Withdrawn
- 2003-02-11 WO PCT/US2003/004184 patent/WO2003068801A2/en active Search and Examination
- 2003-02-11 JP JP2003567927A patent/JP2006506943A/en active Pending
- 2003-02-11 AU AU2003216250A patent/AU2003216250A1/en not_active Abandoned
- 2003-02-11 KR KR10-2004-7012316A patent/KR20040082421A/en not_active Application Discontinuation
- 2003-02-11 MX MXPA04007583A patent/MXPA04007583A/en unknown
- 2003-02-11 US US10/364,953 patent/US20030224397A1/en not_active Abandoned
- 2003-02-11 BR BR0307548-6A patent/BR0307548A/en not_active IP Right Cessation
-
2006
- 2006-10-02 US US11/537,851 patent/US20070037255A1/en not_active Abandoned
-
2008
- 2008-04-02 US US12/061,551 patent/US20080299115A1/en not_active Abandoned
-
2009
- 2009-10-19 US US12/581,574 patent/US20100291072A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632926B1 (en) * | 1998-11-18 | 2003-10-14 | Genentech, Inc. | Antibody variants |
Non-Patent Citations (4)
Title |
---|
FOGOLARI ET AL.: "Simulation of electrostatic effects in Fab-antigen complex formation", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, 2000, pages 4861 - 4869, XP002986093 * |
MULLER ET AL.: "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4.A resolution and mutational analysis of the interface", STRUCTURE, vol. 6, no. 9, 15 September 1998 (1998-09-15), pages 1153 - 1167, XP002986094 * |
See also references of EP1573002A4 * |
SELZER ET AL.: "Rational design of faster associating and tighter binding protein complexes", NATURE STRUCTURAL BIOLOGY, vol. 7, no. 7, July 2000 (2000-07-01), pages 537 - 541, XP008047548 * |
Also Published As
Publication number | Publication date |
---|---|
EP1573002A4 (en) | 2008-07-16 |
EP1573002A2 (en) | 2005-09-14 |
JP2006506943A (en) | 2006-03-02 |
AU2003216250A1 (en) | 2003-09-04 |
KR20040082421A (en) | 2004-09-24 |
MXPA04007583A (en) | 2005-04-25 |
CA2472922A1 (en) | 2003-08-21 |
US20080299115A1 (en) | 2008-12-04 |
BR0307548A (en) | 2006-01-17 |
US20030224397A1 (en) | 2003-12-04 |
US20100291072A1 (en) | 2010-11-18 |
WO2003068801A2 (en) | 2003-08-21 |
US20070037255A1 (en) | 2007-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003068801A3 (en) | Antibody variants with faster antigen association rates | |
HRP20151252T1 (en) | Modified antibody fab fragments | |
IL172871A (en) | Isolated human antibody or antigen-binding fragment thereof, an immunoconjugate, a single chain antibody molecule and a polypeptide comprising the same and uses thereof | |
HK1081647A1 (en) | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses | |
WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
IN2009KN02655A (en) | ||
WO2006039258A3 (en) | Human antibodies against parathyroid hormone | |
WO2004108889A3 (en) | Hybrid antibodies | |
WO2005016111A3 (en) | Antibodies directed to parathyroid hormone (PTH) and uses thereof | |
WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
AU2003265883A1 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
WO2008079995A3 (en) | Conjugate of natriuretic peptide and antibody constant region | |
WO2003048321A3 (en) | Hybrid antibodies | |
WO2004050683A8 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
WO2006081139A3 (en) | Antibodies against interleukin-1 beta | |
WO2005068503A3 (en) | M-csf-specific monoclonal antibody and uses thereof | |
IL176940A (en) | Isolated antibody or an antigen binding fragment thereof that binds ige | |
WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
EP1633785A4 (en) | Human monoclonal antibodies against bacillusanthracis protective antigen | |
EP1607404A4 (en) | Monoclonal antibody and hybridoma producing the same | |
IL172242A0 (en) | Antibodies specific for cancer associated antigen sm5-1 and uses thereof | |
WO2002075274A3 (en) | Method and kit for following neurodegenerative diseases | |
EP1491555A4 (en) | Anti-human hepatoma monoclonal antibody hab18 light/heavy chain variable region gene, and use thereof | |
WO2005026210A3 (en) | Therapeutic binding molecules | |
WO2005023201A3 (en) | Methods for treating rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2472922 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/05725 Country of ref document: ZA Ref document number: 200405725 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163109 Country of ref document: IL Ref document number: 2003216250 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003739759 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 534280 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/007583 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047012316 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003567927 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038081253 Country of ref document: CN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003739759 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0307548 Country of ref document: BR |